Marijuana compounds show promise in treatment of cardiac disease

0

A Nevada company is hoping to develop new medicines for heart failure using compounds in marijuana and a novel therapy identified by a University of Hawaiʻi at Mānoa researcher.

Cannabinoids include psychoactive and non-psychoactive compounds derived from marijuana, both of which have medicinal properties. They exert their effects inside cells after binding to receptor proteins in the cell membranes, such as TRPV1 and the classical cannabinoid receptors, CB1 and CB2.

“Cardiovascular disease is the leading global cause of death, accounting for more than 17.3 million deaths per year, a number that is expected to grow to more than 23.6 million by 2030,” said Dr. Stokes. In the U.S, he explained, this equates to one in three deaths, about one every 40 seconds, and costs the country approximately $316.6 billion a year.

Patients urgently need new drugs that can prevent or reverse the stages of cardiac disease and heart failure, according to Dr. Stokes. He further explained that TRPV1 is clearly a major cellular receptor involved in the progression to heart failure, and there is great potential for the new, proprietary mixtures within the GB Life Sciences portfolio to regulate the TRPV1 cannabinoid receptor.

Continue reading the full article on MedicalXpress

Share.

Comments are closed.